Seasonal and pandemic influenza: A 2007 update on challenges and solutions

Clinical Infectious Diseases

Volumn 46, Issue 7, 2008, Pages 1024-1031

  Monto, Arnold S ^a,b   Whitley, Richard J ^c,d,e,f,g  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c University of Alabama at Birmingham and Children's Hospital   (United States)

^d University of Alabama at Birmingham   (United States)

^e and Clinical Center   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; PLACEBO; RIMANTADINE; ZANAMIVIR;

ARTICLE; CLINICAL TRIAL; CROSS REACTION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PATHOGENICITY; PRIORITY JOURNAL; SEASONAL VARIATION; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; ASIA; BIRDS; COMMUNICABLE DISEASE CONTROL; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE EAST;

EID: 42549119628     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/528720     Document Type: Article

References (49)

1. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002; 76:105-15.
2. World Organization for Animal Health. Update on avian influenza in animals (Type H5). 2007. Available at: http://www.oie.int/downld/ AVIAN%20INFLUENZA/A_AI-Asia.htm. Accessed 14 March 2007.
3. World Health Organization (WHO). Cumulative number of confirmed human cases of avian influenza A/ (H5N1) reported to WHO. Available at: http://www.who.int/csr/disease/avian_influenza/country/en/. Accessed 18 October 2007.
4. World Health Organization (WHO). Update: WHO-confirmed human cases of avian influenza A(H5N1) infection, 25 November 2003-24 November 2006. Available at: http://www.who.int/wer/2007/wer8206.pdf. Accessed 14 March 2007.
5. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006; 355:2186-94.
6. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.
7. Webster RG, Peiris M, Chen H, Guan Y. H5N1 outbreaks and enzootic influenza. Emerg Infect Dis 2006; 12:3-8.
8. Garcia-Sastre A, Whitley RJ. Lessons learned from reconstructing the 1918 influenza pandemic. J Infect Dis 2006; 194(Suppl 2):127-32.
9. de Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-72.
10. Fauci A. Seasonal and influenza preparedness: science and public health. In: Program and abstracts of the 2nd Annual Seasonal and Pandemic Influenza Conference (Arlington, VA). 2007.
11. National Institute of Allergy and Infectious Diseases (NIAID). 2,000 Influenza virus genomes now completed and publicly accessible. Available at: http://www3.niaid.nih.gov/news/newsreleases/2007s/flu2000.htm. Accessed 23 March 2007.
12. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
13. Patel SM, Atmar RL, Sahly HE, Cate TR, Keitel WA. A randomized, open-label, phase I clinical trial comparing the safety, reactogenicity, and immunogenicity of booster immunization with inactivated influenza A/H5N1 vaccine administered by the intradermal (ID) or the intramuscular (IM) route among healthy adults [abstract LB-5]. In: Program and abstracts of the 44th Annual Meeting of the Infectious Diseases Society of America (Toronto). Alexandria, VA: Infectious Diseases Society of America, 2006:64.
14. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657-64.
15. Lin J, Zhang J, Dong X, Fang H, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991-7.
16. GlaxoSmithKline (GSK). New studies indicate GSK's pre-pandemic influenza vaccine can protect against different strains of H5N1. Available at: http://www.gsk.com/ControllerServlet?appId=4pageId=402newsid=989. Accessed March 2007.
17. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:1687-93.
18. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249-57.
19. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-73.
20. Moscona A, McKimm-Breschkin J. News about influenza B drug resistance that cannot be ignored. JAMA 2007; 297:1492-3.
21. Schunemann HJ, Hill SR, Kakad M, et al. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007; 7:21-31.
22. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007; 51:1414-24.
23. Arnold CS, Zacks MA, Dziuba N. et al. Injectable peramivir promotes survival in mice and ferrets infected with highly pathogenic avian influenza A/Vietnam/1203/04 (H5N1) and phase 1 clinical data support evaluation of peramivir in the treatment of seasonal and potentially life-threatening influenza. In: Program and abstracts of the 2nd Annual Seasonal and Pandemic Influenza Conference (Arlington, VA). 2007.
24. Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49:981-6.
25. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50:1470-9.
26. European Centre for Disease Prevention and Control. 2007. Technical report pandemic influenza preparedness in the EU Status Report as of Autumn 2006. Available at: http://www.ecdc.eu.int/pdf/Pandemic_preparedness.pdf. Accessed 23 April 2007.
27. Republique Francaise. Service d'information du gouvernement. Le site interministeriel de preparation a un risque de pandemie grippale. Available at: http://www.grippeaviaire.gouv.fr. Accessed 8 February 2008.
28. Tam T, Grimsrud K. The Canadian pandemic influenza plan for the health sector. Available at: http://www.phac-aspc.gc.ca/cpip-pclcpi/pdf-e/CPIP-2006_e. pdf. Accessed 23 April 2007.
29. The White House. News and Policies, 2006. The security and prosperity partnership of North America: next steps. Available at: http://www.whitehouse. gov/news/releases/2006/03/20060331-1.html. Accessed 23 April 2007.
30. Centers for Disease Control and Prevention. Federal planning and response activities. Available at: http://www.pandemicflu.gov/plan/federal/index.html. Accessed 8 March 2007.
31. Centers for Disease Control and Prevention. Community strategy for pandemic influenza mitigation. Available at: http://www.pandemicflu.gov/plan/ community/commitigation.html. Accessed 8 March 2007.
32. Centers for Disease Control and Prevention. Pandemic planning assumptions. Available at: http://www.pandemicflu.gov/plan/pandplan.html. Accessed 8 March 2007.
33. Toner E, Waldhorn R, Maldin B, et al. Hospital preparedness for pandemic influenza. Biosecur Bioterror 2006; 4:207-17.
34. Centers for Disease Control and Prevention. Interim pre-pandemic planning guidance: community strategy for pandemic influenza mitigation in the United States: Early targeted layered use of non-pharmaceutical interventions and pandemic severity index. Available at: http://www.pandemicflu.gov/plan/ community/community_mitigation.pdf. Accessed 24 June 2007.
35. Institute of Medicine. Board on population health and public health practice. Modeling community containment for pandemic influenza. Available at: http://books.nap.edu/catalog.php?record_id=11800. Accessed 8 February 2008.
36. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2007-2008 Northern Hemisphere influenza season. Available at: http://www.who.int/csr/disease/influenza/recommendations2007/ north/en/. Accessed 13 June 2007.
37. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284:1655-63.
38. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513-22.
39. Centers for Disease Control and Prevention. National InfluenzaVaccine Summit newsletter 2006. 2006. Available at: http://www.cdc.gov/flu/ professionals/flubulletin.htm. Accessed 6 March 2007.
40. Centers for Disease Control and Prevention. Childhood influenza vaccination coverage-United States, 2004-05 influenza season. MMWR Morb Mortal Wkly Rep 2006; 55:1062-5.
41. Center for Infectious Disease Research and Policy News. HHS updates pandemic stockpile totals and planning efforts. Available at: http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/jul1907update. html. Accessed 25 July 2007.
42. France E, Woodworth T, Ward. Preparing for pandemic flu: a mass flu clinic exercise in Colorado. In: Program and abstracts of the 2nd Annual Seasonal and Pandemic Influenza Conference (Arlington, VA). 2007.
43. Hull H, Frauendienst R, Gunderson S, Monsen S. Is school-based immunization feasible in the US? In: Program and abstracts of the 2nd Annual Seasonal and Pandemic Influenza Conference (Arlington, VA). 2007.
44. Pearson M, Bridges C, Harper S; Healthcare Infection Control Practices Advisory Committee (HICPAC); Advisory Committee on Immunization Practices (ACIP). Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-16.
45. Burls A, Jordan R, Barton P, et al. Vaccinating healthcare workers against influenza to protect the vulnerable - is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine 2006; 24:4212-21.
46. Joint Commission on the Accreditation of Healthcare Organizations. Joint commission establishes infection control standard to address influenza vaccines for staff, 2006. Available at: http://www.jointcommission.org/NewsRoom/ NewsReleases/nr_06_13_06.htm. Accessed 11 July 2007.
47. Kimura AC, Nguyen CN, Higa JI, Hurwitz EL, Vugia DJ. The effectiveness of vaccine day and educational interventions on influenza vaccine coverage among health care workers at long-term care facilities. Am J Public Health 2007; 97:684-90.
48. Osterholm MT. Preparing for the next pandemic. N Engl J Med 2005; 352:1839-42.
49. Harvard School of Public Health. Pandemic influenza and the public: survey findings. 2006. Available at: http://www.hsph.harvard.edu/news/ press-releases/2006-releases/press10262006.html. Accessed 24 July 2007.